Oncotarget strategies for herpes simplex virus-1

Current Gene Therapy

Volumn 16, Issue 2, 2016, Pages 130-143

  Zhang, Lumin ^a,b,c   Tatsuya, Tsurumi ^b   Nishiyama, Yukihiro ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti tumor; Glioma; ICP34.5; Oncolytic HSV 1 virotherapy; Oncotarget

Indexed keywords

ACICLOVIR; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; G 207; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INITIATION FACTOR 2; INTERLEUKIN 12; INTERLEUKIN 4; LAT PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN KINASE R; PROTEIN VP16; RAS PROTEIN; RIBONUCLEOTIDE REDUCTASE; THYMIDINE KINASE; TOLL LIKE RECEPTOR; URACIL DNA GLYCOSIDASE; VIRUS PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DNA MODIFICATION; GENE EXPRESSION; GENE LOSS; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; ANIMAL; CLINICAL TRIAL (TOPIC); GENE VECTOR; GENETICS; HERPES SIMPLEX; NEOPLASM; TRANSGENE; VIROLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC VECTORS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; NEOPLASMS; TRANSGENES;

EID: 84966350652     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523216666160331130153     Document Type: Article

References (236)

1. Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3(6): 639-45.
2. Zeh HJ, Bartlett DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther 2002; 9(12): 1001-12.
3. Kirn DH. Replication-selective microbiological agents: fighting cancer with targeted germ warfare. J Clin Invest 2000; 105(7): 837-9.
4. Gromeier M, Lachmann S, Rosenfeld MR, et al. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA 2000; 97(12): 6803-8.
5. Cassel WA, Garrett RE. Newcastle disease virus as an antineoplastic agent. Cancer 1965; 18: 863-8.
6. Norman KL, Hirasawa K, Yang AD, et al. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004; 101(30): 11099-104.
7. Grote D, Russell SJ, Cornu TI, et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001; 97(12): 3746-54.
8. Wang G, Barrett JW, Stanford M, et al. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci USA 2006; 103(12): 4640-5.
9. Koslowski KM, Shaver PR, Casey JT, 2nd, et al. Physical and functional interactions between the herpes simplex virus UL15 and UL28 DNA cleavage and packaging proteins. J Virol 1999; 73(2): 1704-7.
10. Hamid O, Varterasian ML, Wadler S, et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21(8): 1498-504.
11. Geller AI, Keyomarsi K, Bryan J, et al. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci USA 1990; 87(22): 8950-4.
12. de Leeuw OS, Hartog L, Koch G, et al. Effect of fusion protein cleavage site mutations on virulence of Newcastle disease virus: non-virulent cleavage site mutants revert to virulence after one passage in chicken brain. J Gen Virol 2003; 84(Pt 2): 475-84.
13. Roizman B. The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA 1996; 93(21): 11307-12.
14. Fukuhara H, Ino Y, Kuroda T, et al. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosomemediated system. Cancer Res 2005; 65(23): 10663-8.
15. Bradley H, Markowitz LE, Gibson T, et al. Seroprevalence of herpes simplex virus types 1 and 2-United States, 1999-2010. J Infect Dis 2014; 209(3): 325-33.
16. Post LE, Roizman B. A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth. Cell 1981; 25(1): 227-32.
17. Todo T. "Armed" oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh Migr 2008; 2(3): 208-13.
18. Rajcani J, Andrea V, Ingeborg R. Peculiarities of herpes simplex virus (HSV) transcription: an overview. Virus Genes 2004; 28(3): 293-310.
19. Nishiyama Y. Herpes simplex virus gene products: the accessories reflect her lifestyle well. Rev Med Virol 2004; 14(1): 33-46.
20. Boehmer PE, Lehman IR. Herpes simplex virus DNA replication. Annu Rev Biochem 1997; 66: 347-84.
21. Mohr I. To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control. Oncogene 2005; 24(52): 7697-709.
22. Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis. Neoplasia 1999; 1(5): 387-401.
23. Jackson SA, DeLuca NA. Relationship of herpes simplex virus genome configuration to productive and persistent infections. Proc Natl Acad Sci USA 2003; 100(13): 7871-6.
24. Lilley CE, Carson CT, Muotri AR, et al. DNA repair proteins affect the lifecycle of herpes simplex virus 1. Proc Natl Acad Sci USA 2005; 102(16): 5844-9.
25. Sobol PT, Hummel JL, Rodrigues RM, et al. PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses. Gene Ther 2009; 16(9): 1077-87.
26. Sobol PT, Mossman KL. ICP0 prevents RNase L-independent rRNA cleavage in herpes simplex virus type 1-infected cells. J Virol 2006; 80(1): 218-25.
27. Yokota S, Yokosawa N, Okabayashi T, et al. Induction of suppressor of cytokine signaling-3 by herpes simplex virus type 1 contributes to inhibition of the interferon signaling pathway. J Virol 2004; 78(12): 6282-6.
28. Hummel JL, Safroneeva E, Mossman KL. The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol Ther 2005; 12(6): 1101-10.
29. Workenhe ST, Simmons G, Pol JG, et al. Immunogenic HSVmediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol Ther 2014; 22(1): 123-31.
30. Krisky DM, Marconi PC, Oligino TJ, et al. Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther 1998; 5(11): 1517-30.
31. Wu N, Watkins SC, Schaffer PA, et al. Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J Virol 1996; 70(9): 6358-69.
32. Preston CM, Mabbs R, Nicholl MJ. Construction and characterization of herpes simplex virus type 1 mutants with conditional defects in immediate early gene expression. Virology 1997; 229(1): 228-39.
33. Samaniego LA, Wu N, DeLuca NA. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol 1997; 71(6): 4614-25.
34. Eisenberg DP, Carpenter SG, Adusumilli PS, et al. Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway. Surgery 2010; 148(2): 325-34.
35. Gholami S, Chen CH, Gao S, et al. Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. Cancer Gene Ther 2014; 21(7): 283-9.
36. Mullerad M, Bochner BH, Adusumilli PS, et al. Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. J Urol 2005; 174(2): 741-6.
37. Stiles BM, Adusumilli PS, Bhargava A, et al. Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer. Cancer Gene Ther 2006; 13(1): 53-64.
38. Wong RJ, Joe JK, Kim SH, et al. Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther 2002; 13(10): 1213-23.
39. Hill A, Jugovic P, York I, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375(6530): 411-5.
40. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and antitumour properties. Gene Ther 2003; 10(4): 292-303.
41. Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001; 98(11): 6396-401.
42. Kulu Y, Dorfman JD, Kuruppu D, et al. Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice. Cancer Gene Ther 2009; 16(4): 291-7.
43. Spear MA, Sun F, Eling DJ, et al. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase- defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther 2000; 7(7): 1051-9.
44. Nawa A, Nozawa N, Goshima F, et al. Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model. Gynecol Oncol 2003; 91(1): 81-8.
45. Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001; 3(8): 745-50.
46. Luo C, Mori I, Goshima F, et al. Replication-competent, oncolytic herpes simplex virus type 1 mutants induce a bystander effect following ganciclovir treatment. J Gene Med 2007; 9(10): 875-83.
47. Boviatsis EJ, Scharf JM, Chase M, et al. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther 1994; 1(5): 323-31.
48. Kelly K, Brader P, Rein A, et al. Attenuated multimutated herpes simplex virus-1 effectively treats prostate carcinomas with neural invasion while preserving nerve function. FASEB J 2008; 22(6): 1839-48.
49. Bennett JJ, Tjuvajev J, Johnson P, et al. Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nat Med 2001; 7(7): 859-63.
50. Jacobs A, Tjuvajev JG, Dubrovin M, et al. Positron emission tomography- based imaging of transgene expression mediated by replication- conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 2001; 61(7): 2983-95.
51. Mullerad M, Eisenberg DP, Akhurst TJ, et al. Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus. Mol Imaging Biol 2006; 8(1): 30-5.
52. Valyi-Nagy T, Fareed MU, O’Keefe JS, et al. The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol 1994; 75(Pt 8): 2059-63.
53. Kanai R, Zaupa C, Sgubin D, et al. Effect of gamma34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol 2012; 86(8): 4420-31.
54. Li Y, Zhang C, Chen X, et al. ICP34.5 protein of herpes simplex virus facilitates the initiation of protein translation by bridging eukaryotic initiation factor 2alpha (eIF2alpha) and protein phosphatase 1. J Biol Chem 2011; 286(28): 24785-92.
55. He B, Gross M, Roizman B. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997; 94(3): 843-8.
56. Tang S, Guo N, Patel A, et al. Herpes simplex virus 2 expresses a novel form of ICP34.5, a major viral neurovirulence factor, through regulated alternative splicing. J Virol 2013; 87(10): 5820-30.
57. Wu DY, Tkachuck DC, Roberson RS, et al. The human SNF5/INI1 protein facilitates the function of the growth arrest and DNA damage- inducible protein (GADD34) and modulates GADD34-bound protein phosphatase-1 activity. J Biol Chem 2002; 277(31): 27706-15.
58. Sarinella F, Calistri A, Sette P, et al. Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Rasactivation, but on the PI 3-kinase pathway. Gene Ther 2006; 13(14): 1080-7.
59. Veerapong J, Bickenbach KA, Shao MY, et al. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res 2007; 67(17): 8301-6.
60. Farassati F, Pan W, Yamoutpour F, et al. Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am J Pathol 2008; 173(6): 1861-72.
61. Trgovcich J, Johnson D, Roizman B. Cell surface major histocompatibility complex class II proteins are regulated by the products of the gamma(1)34.5 and U(L)41 genes of herpes simplex virus 1. J Virol 2002; 76(14): 6974-86.
62. Broberg EK, Hukkanen V. Immune response to herpes simplex virus and gamma134.5 deleted HSV vectors. Curr Gene Ther 2005; 5(5): 523-30.
63. Broberg EK, Peltoniemi J, Nygardas M, et al. Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice. J Virol 2004; 78(23): 13139-52.
64. Meshii N, Takahashi G, Okunaga S, et al. Enhancement of systemic tumor immunity for squamous cell carcinoma cells by an oncolytic herpes simplex virus. Cancer Gene Ther 2013; 20(9): 493-8.
65. Detta A, Harland J, Hanif I, et al. Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours. J Gene Med 2003; 5(8): 681-9.
66. Quigg M, Mairs RJ, Brown SM, et al. Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy. Med Chem 2005; 1(5): 423-9.
67. Mace AT, Harrow SJ, Ganly I, et al. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma. Acta Otolaryngol 2007; 127(8): 880-7.
68. Mace AT, Ganly I, Soutar DS, et al. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck 2008; 30(8): 1045-51.
69. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000; 7(10): 859-66.
70. Papanastassiou V, Rampling R, Fraser M, et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 2002; 9(6): 398-406.
71. Harrow S, Papanastassiou V, Harland J, et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 2004; 11(22): 1648-58.
72. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1(9): 938-43.
73. Coen DM, Goldstein DJ, Weller SK. Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob Agents Chemother 1989; 33(8): 1395-9.
74. Walker JR, McGeagh KG, Sundaresan P, et al. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999; 10(13): 2237-43.
75. Chahlavi A, Todo T, Martuza RL, et al. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999; 1(2): 162-9.
76. Cinatl J Jr., Cinatl J, Michaelis M, et al. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res 2003; 63(7): 1508-14.
77. Hunter WD, Martuza RL, Feigenbaum F, et al. Attenuated, replication- competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999; 73(8): 6319-26.
78. Sundaresan P, Hunter WD, Martuza RL, et al. Attenuated, replication- competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 2000; 74(8): 3832-41.
79. Todo T, Feigenbaum F, Rabkin SD, et al. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther 2000; 2(6): 588-95.
80. Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009; 17(1): 199-207.
81. Kirn DH. A tale of two trials: selectively replicating herpesviruses for brain tumors. Gene Ther 2000; 7(10): 815-6.
82. Markert JM, Razdan SN, Kuo HC, et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther 2014; 22(5): 1048-55.
83. Lou E. Oncolytic viral therapy and immunotherapy of malignant brain tumors: two potential new approaches of translational research. Ann Med 2004; 36(1): 2-8.
84. Shah AC, Benos D, Gillespie GY, et al. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol 2003; 65(3): 203-26.
85. Yazaki T, Manz HJ, Rabkin SD, et al. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 1995; 55(21): 4752-6.
86. Wu A, Mazumder A, Martuza RL, et al. Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res 2001; 61(7): 3009-15.
87. Coukos G, Makrigiannakis A, Montas S, et al. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 2000; 7(2): 275-83.
88. Carew JF, Kooby DA, Halterman MW, et al. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 1999; 10(10): 1599-606.
89. Cozzi PJ, Burke PB, Bhargav A, et al. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate 2002; 53(2): 95-100.
90. Nakano K, Todo T, Chijiiwa K, et al. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol Ther 2001; 3(4): 431-7.
91. Oyama M, Ohigashi T, Hoshi M, et al. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther 2000; 11(12): 1683-93.
92. Oyama M, Yazaki T, Ohigashi T, et al. Application of conditionally replicating herpes vector for gene therapy treatment of urologic neoplasms. Mol Urol 2000; 4(2): 83-7.
93. Oyama M, Ohigashi T, Hoshi M, et al. Treatment of human renal cell carcinoma by a conditionally replicating herpes vector G207. J Urol 2001; 165(4): 1274-8.
94. Lee JH, Federoff HJ, Schoeniger LO. G207, modified herpes simplex virus type 1, kills human pancreatic cancer cells in vitro. J Gastrointest Surg 1999; 3(2): 127-31.
95. Kooby DA, Carew JF, Halterman MW, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-1 (G207). FASEB J 1999; 13(11): 1325-34.
96. Endo T, Toda M, Watanabe M, et al. In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther 2002; 9(2): 142-8.
97. Bateman A, Bullough F, Murphy S, et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immunemediated control of tumor growth. Cancer Res 2000; 60(6): 1492-7.
98. Higuchi H, Bronk SF, Bateman A, et al. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res 2000; 60(22): 6396-402.
99. Fu X, Tao L, Jin A, et al. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 2003; 7(6): 748-54.
100. Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 2002; 62(8): 2306-12.
101. Fu X, Tao L, Cai R, et al. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol Ther 2006; 13(5): 882-90.
102. Nakamori M, Fu X, Meng F, et al. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res 2003; 9(7): 2727-33.
103. Ogawa F, Takaoka H, Iwai S, et al. Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma. Anticancer Res 2008; 28(6A): 3637-45.
104. Fu X, Tao L, Li M, et al. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin Cancer Res 2006; 12(10): 3152-7.
105. Peters GA, Khoo D, Mohr I, et al. Inhibition of PACT-mediated activation of PKR by the herpes simplex virus type 1 Us11 protein. J Virol 2002; 76(21): 11054-64.
106. Poppers J, Mulvey M, Khoo D, et al. Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein. J Virol 2000; 74(23): 11215-21.
107. Giraud S, Diaz-Latoud C, Hacot S, et al. US11 of herpes simplex virus type 1 interacts with HIPK2 and antagonizes HIPK2-induced cell growth arrest. J Virol 2004; 78(6): 2984-93.
108. Mohr I, Gluzman Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J 1996; 15(17): 4759-66.
109. Liu R, Varghese S, Rabkin SD. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res 2005; 65(4): 1532-40.
110. Li J, Zeng W, Huang Y, et al. Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther 2012; 19(10): 707-14.
111. Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, et al. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther 2007; 14(5): 460-7.
112. Antoszczyk S, Spyra M, Mautner VF, et al. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro Oncol 2014; 16(8): 1057-66.
113. Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastomaderived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 2009; 69(8): 3472-81.
114. Wang J, Xu L, Zeng W, et al. Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta. Cancer Cell Int 2014; 14(1): 83.
115. Kelly KJ, Wong J, Fong Y. Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy. Expert Opin Investig Drugs 2008; 17(7): 1105-13.
116. Wong RJ, Kim SH, Joe JK, et al. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001; 193(1): 12-21.
117. Bennett JJ, Delman KA, Burt BM, et al. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 2002; 9(11): 935-45.
118. Cozzi PJ, Malhotra S, McAuliffe P, et al. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J 2001; 15(7): 1306-8.
119. McAuliffe PF, Jarnagin WR, Johnson P, et al. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg 2000; 4(6): 580-8.
120. Fong Y, Kim T, Bhargava A, et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 2009; 17(2): 389-94.
121. Geevarghese SK, Geller DA, de Haan HA, et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 2010; 21(9): 1119-28.
122. Ko D, Hawkins L, Yu DC. Development of transcriptionally regulated oncolytic adenoviruses. Oncogene 2005; 24(52): 7763-74.
123. Lee CY, Bu LX, DeBenedetti A, et al. Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors. Mol Ther 2010; 18(5): 929-35.
124. Grandi P, Fernandez J, Szentirmai O, et al. Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIIIbearing tumor cells. Cancer Gene Ther 2010; 17(9): 655-63.
125. Chung RY, Saeki Y, Chiocca EA. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol 1999; 73(9): 7556-64.
126. Gayral M, Lulka H, Hanoun N, et al. Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors. Hum Gene Ther 2014.
127. Nakamura H, Kasuya H, Mullen JT, et al. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 2002; 109(7): 871-82.
128. Gayral M, Lulka H, Hanoun N, et al. Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors. Hum Gene Ther 2015; 26(2): 104-13.
129. Menotti L, Nicoletti G, Gatta V, et al. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci USA 2009; 106(22): 9039-44.
130. Nanni P, Gatta V, Menotti L, et al. Preclinical therapy of disseminated HER-2(+) ovarian and breast carcinomas with a HER-2- retargeted oncolytic herpesvirus. PLoS Pathog 2013; 9(1): e1003155.
131. Kasuya H, Pawlik TM, Mullen JT, et al. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res 2004; 64(7): 2561-7.
132. Maldonado AR, Klanke C, Jegga AG, et al. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors. J Gene Med 2010; 12(7): 613-23.
133. Kambara H, Okano H, Chiocca EA, et al. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005; 65(7): 2832-9.
134. Kanai R, Tomita H, Shinoda A, et al. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence. Gene Ther 2006; 13(2): 106-16.
135. Yao F, Murakami N, Bleiziffer O, et al. Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy. J Virol 2010; 84(16): 8163-71.
136. Yoo JY, Haseley A, Bratasz A, et al. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"- expressing oncolytic virus. Mol Ther 2012; 20(2): 287-97.
137. Zhang W, Ge K, Zhao Q, et al. A novel oHSV-1 targeting telomerase reverse transcriptase-positive cancer cells via tumor-specific promoters regulating the expression of ICP4. Oncotarget 2015.
138. Chambers R, Gillespie GY, Soroceanu L, et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA 1995; 92(5): 1411-5.
139. Pin RH, Reinblatt M, Fong Y. Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma. Ann Surg 2004; 240(4): 659-65; discussion 65-6.
140. Reinblatt M, Pin RH, Fong Y. Carcinoembryonic antigen directed herpes viral oncolysis improves selectivity and activity in colorectal cancer. Surgery 2004; 136(3): 579-84.
141. Pin RH, Reinblatt M, Fong Y. Employing tumor hypoxia to enhance oncolytic viral therapy in breast cancer. Surgery 2004; 136(2): 199-204.
142. Reinblatt M, Pin RH, Federoff HJ, et al. Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases. Ann Surg 2004; 239(6): 892-9.
143. Valyi-Nagy K, Dosa S, Kovacs SK, et al. Identification of virus resistant tumor cell subpopulations in three-dimensional uveal melanoma cultures. Cancer Gene Ther 2010; 17(4): 223-34.
144. Voros A, Kormos B, Valyi-Nagy T, et al. Increased resistance of breast, prostate, and embryonic carcinoma cells against herpes simplex virus in three-dimensional cultures. ISRN Oncol 2013; 2013: 104913.
145. Kolodkin-Gal D, Zamir G, Edden Y, et al. Herpes simplex virus type 1 preferentially targets human colon carcinoma: role of extracellular matrix. J Virol 2008; 82(2): 999-1010.
146. Huszthy PC, Immervoll H, Wang J, et al. Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment. Gene Ther 2010; 17(2): 202-16.
147. McKee TD, Grandi P, Mok W, et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006; 66(5): 2509-13.
148. Mori I, Goshima F, Ito H, et al. The vomeronasal chemosensory system as a route of neuroinvasion by herpes simplex virus. Virology 2005; 334(1): 51-8.
149. Mori I, Liu B, Goshima F, et al. HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2. Microbes Infect 2005; 7(15): 1492-500.
150. Nishiyama Y, Kimura H, Daikoku T. Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus types 1 and 2. J Virol 1991; 65(8): 4520-4.
151. Takakuwa H, Goshima F, Nozawa N, et al. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol 2003; 148(4): 813-25.
152. Koshizuka T, Goshima F, Takakuwa H, et al. Identification and characterization of the UL56 gene product of herpes simplex virus type 2. J Virol 2002; 76(13): 6718-28.
153. Koshizuka T, Kawaguchi Y, Goshima F, et al. Association of two membrane proteins encoded by herpes simplex virus type 2, UL11 and UL56. Virus Genes 2006; 32(2): 153-63.
154. Kimata H, Takakuwa H, Goshima F, et al. Effective treatment of disseminated peritoneal colon cancer with new replicationcompetent herpes simplex viruses. Hepatogastroenterology 2003; 50(52): 961-6.
155. Peles E, Rosen H, Darai G, et al. Importance of the HpaI-P sequence for herpes simplex virus-1 replication in the adrenal glands. Arch Virol 1990; 113(3-4): 151-63.
156. Yuan X, Li J, Shan Y, et al. Subcellular localization and membrane association of SARS-CoV 3a protein. Virus Res 2005; 109(2): 191-202.
157. Perng GC, Dunkel EC, Geary PA, et al. The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J Virol 1994; 68(12): 8045-55.
158. Yamada H, Jiang YM, Oshima S, et al. Characterization of the UL55 gene product of herpes simplex virus type 2. J Gen Virol 1998; 79 (Pt 8): 1989-95.
159. Zhang L, Daikoku T, Ohtake K, et al. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10. J Virol Methods 2006; 137(2): 177-83.
160. Harland J, Dunn P, Cameron E, et al. The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNAbinding complex with proliferating cell nuclear antigen and HSV replication proteins. J Neurovirol 2003; 9(4): 477-88.
161. Mao H, Rosenthal KS. Strain-dependent structural variants of herpes simplex virus type 1 ICP34.5 determine viral plaque size, efficiency of glycoprotein processing, and viral release and neuroinvasive disease potential. J Virol 2003; 77(6): 3409-17.
162. Watanabe D, Goshima F, Mori I, et al. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J Dermatol Sci 2008; 50(3): 185-96.
163. Fujiwara S, Nawa A, Luo C, et al. Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer. Cancer Gene Ther 2011; 18(2): 77-86.
164. Kohno S, Luo C, Goshima F, et al. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer. Urology 2005; 66(5): 1116-21.
165. Teshigahara O, Goshima F, Takao K, et al. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10. J Surg Oncol 2004; 85(1): 42-7.
166. Sahin TT, Kasuya H, Nomura N, et al. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer. Cancer Gene Ther 2012; 19(4): 229-37.
167. Kimata H, Imai T, Kikumori T, et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol 2006; 13(8): 1078-84.
168. Fujimoto Y, Mizuno T, Sugiura S, et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol 2006; 126(10): 1115-7.
169. Ino Y, Saeki Y, Fukuhara H, et al. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 2006; 12(2): 643-52.
170. Parker JN, Gillespie GY, Love CE, et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000; 97(5): 2208-13.
171. Hardcastle J, Kurozumi K, Dmitrieva N, et al. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 2010; 18(2): 285-94.
172. Conner J, Braidwood L. Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy. Cancer Gene Ther 2012; 19(7): 499-507.
173. Son SH, Yu E, Choi EK, et al. Promyelocytic leukemia proteininduced growth suppression and cell death in liver cancer cells. Cancer Gene Ther 2005; 12(1): 1-11.
174. Wong RJ, Patel SG, Kim S, et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 2001; 12(3): 253-65.
175. Roth JC, Cassady KA, Cody JJ, et al. Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev 2014; 25(1): 16-27.
176. Wong RJ, Chan MK, Yu Z, et al. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 2004; 10(13): 4509-16.
177. Varghese S, Rabkin SD, Liu R, et al. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 2006; 13(3): 253-65.
178. Wong RJ, Chan MK, Yu Z, et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 2004; 10(1 Pt 1): 251-9.
179. Jarnagin WR, Zager JS, Klimstra D, et al. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Ther 2003; 10(3): 215-23.
180. Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17(3): 718-30.
181. Simpson GR, Horvath A, Annels NE, et al. Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. Br J Cancer 2012; 106(3): 496-507.
182. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27(34): 5763-71.
183. Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010; 16(15): 4005-15.
184. Kaufman HL, Bines SD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010; 6(6): 941-9.
185. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33(25): 2780-8.
186. Sena-Esteves M, Saeki Y, Fraefel C, et al. HSV-1 amplicon vectors- simplicity and versatility. Mol Ther 2000; 2(1): 9-15.
187. Kohno SI, Luo C, Nawa A, et al. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colonystimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther 2007; 14(11): 918-26.
188. Ishida D, Nawa A, Tanino T, et al. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus. Cancer Lett 2010; 288(1): 17-27.
189. Zager JS, Delman KA, Malhotra S, et al. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Mol Med 2001; 7(8): 561-8.
190. Carew JF, Kooby DA, Halterman MW, et al. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol Ther 2001; 4(3): 250-6.
191. Goshima F, Esaki S, Luo C, et al. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer. Int J Cancer 2014; 134(12): 2865-77.
192. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7(10): 867-74.
193. Kemeny N, Brown K, Covey A, et al. Phase I, open-label, doseescalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006; 17(12): 1214-24.
194. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001; 357(9255): 525-6.
195. Mohr I, Sternberg D, Ward S, et al. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 2001; 75(11): 5189-96.
196. Mehta H, Muller J, Markovitz NS. Ultrastructural analysis of ICP34.5- herpes simplex virus 1 replication in mouse brain cells in vivo. J Virol 2010; 84(21): 10982-90.
197. Advani SJ, Markert JM, Sood RF, et al. Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther 2011; 18(11): 1098-102.
198. Blank SV, Rubin SC, Coukos G, et al. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum Gene Ther 2002; 13(5): 627-39.
199. Bennett JJ, Adusumilli P, Petrowsky H, et al. Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J 2004; 18(9): 1001-3.
200. Workenhe ST, Pol JG, Lichty BD, et al. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunol Res 2013; 1(5): 309-19.
201. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 1998; 16(5): 444-8.
202. Currier MA, Gillespie RA, Sawtell NM, et al. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther 2008; 16(5): 879-85.
203. Tyminski E, Leroy S, Terada K, et al. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res 2005; 65(15): 6850-7.
204. Hayashi K, Hooper LC, Chin MS, et al. Herpes simplex virus 1 (HSV-1) DNA and immune complex (HSV-1-human IgG) elicit vigorous interleukin 6 release from infected corneal cells via Tolllike receptors. J Gen Virol 2006; 87(Pt 8): 2161-9.
205. Beutler B, Jiang Z, Georgel P, et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol 2006; 24: 353-89.
206. Wuest T, Austin BA, Uematsu S, et al. Intact TRL 9 and type I interferon signaling pathways are required to augment HSV-1 induced corneal CXCL9 and CXCL10. J Neuroimmunol 2006; 179(1-2): 46-52.
207. Schlee M, Hornung V, Hartmann G. siRNA and isRNA: Two edges of one sword. Mol Ther 2006; 14(4): 463-70.
208. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407(6805): 770-6.
209. Liu TC, Kirn D. Viruses with deletions in antiapoptotic genes as potential oncolytic agents. Oncogene 2005; 24(40): 6069-79.
210. Aubert M, Blaho JA. Modulation of apoptosis during herpes simplex virus infection in human cells. Microbes Infect 2001; 3(10): 859-66.
211. Benencia F, Courreges MC, Conejo-Garcia JR, et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005; 12(5): 789-802.
212. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999; 59(2): 410-3.
213. Farrell CJ, Zaupa C, Barnard Z, et al. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res 2008; 14(23): 7711-6.
214. Meisen WH, Wohleb ES, Jaime-Ramirez AC, et al. The impact of macrophage and microglia-secreted TNFalpha on oncolytic HSV-1 therapy in the glioblastoma tumor microenvironment. Clin Cancer Res 2015.
215. Valyi-Nagy T, Gesser RM, Raengsakulrach B, et al. A thymidine kinase-negative HSV-1 strain establishes a persistent infection in SCID mice that features uncontrolled peripheral replication but only marginal nervous system involvement. Virology 1994; 199(2): 484-90.
216. Kaplitt MG, Tjuvajev JG, Leib DA, et al. Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J Neurooncol 1994; 19(2): 137-47.
217. Huang Q, Vonsattel JP, Schaffer PA, et al. Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study. Exp Neurol 1992; 115(3): 303-16.
218. Jia WW, McDermott M, Goldie J, et al. Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J Natl Cancer Inst 1994; 86(16): 1209-15.
219. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 1988; 166(1): 41-51.
220. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62(1): 196-205.
221. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988; 158(3): 602-14.
222. Chou J, Kern ER, Whitley RJ, et al. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990; 250(4985): 1262-6.
223. Delman KA, Bennett JJ, Zager JS, et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 2000; 11(18): 2465-72.
224. Bennett JJ, Malhotra S, Wong RJ, et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg 2001; 233(6): 819-26.
225. Whitley RJ, Kern ER, Chatterjee S, et al. Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J Clin Invest 1993; 91(6): 2837-43.
226. Kramm CM, Chase M, Herrlinger U, et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997; 8(17): 2057-68.
227. Aghi M, Chou TC, Suling K, et al. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/ rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999; 59(16): 3861-5.
228. Pyles RB, Warnick RE, Chalk CL, et al. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther 1997; 8(5): 533-44.
229. Suter M, Lew AM, Grob P, et al. BAC-VAC, a novel generation of (DNA) vaccines: A bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1. Proc Natl Acad Sci USA 1999; 96(22): 12697-702.
230. He B, Chou J, Brandimarti R, et al. Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 1997; 71(8): 6049-54.
231. Mossman KL, Smiley JR. Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 renders expression of the immediate-early genes almost entirely dependent on ICP0. J Virol 1999; 73(12): 9726-33.
232. Leib DA, Alexander DE, Cox D, et al. Interaction of ICP34.5 with Beclin 1 modulates herpes simplex virus type 1 pathogenesis through control of CD4+ T-cell responses. J Virol 2009; 83(23): 12164-71.
233. Bloom DC, Feller J, McAnany P, et al. Replication-competent controlled herpes simplex virus. J Virol 2015; 89(20): 10668-79.
234. Kasuya H, Kodera Y, Nakao A, et al. Phase I dose-escalation clinical trial of HF10 oncolytic herpes virus in 17 japanese patients with advanced cancer. Hepatogastroenterology 2014; 61(131): 599-605.
235. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9(12): 967-78.
236. Roizman B, Taddeo B. The strategy of herpes simplex virus replication and takeover of the host cell. In: Arvin A, Campadelli-Fiume G, Mocarski E, Patrick SM, Bernard R, Richard W and Koichi Y Eds. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge 2007.